Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options

Affiliations

¹ Department of Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
² Department of Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. Electronic address: edkim@mdanderson.org.

Editorial

W N William Jr et al. Ann Oncol. 2009 Sep.

. 2009 Sep;20(9):1455-1457.

doi: 10.1093/annonc/mdp387.

¹ Department of Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
² Department of Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. Electronic address: edkim@mdanderson.org.

No abstract available

Comment in

Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice.
Tassinari D, Drudi F, Lazzari-Agli L, Tombesi P, Sartori S. Tassinari D, et al. Ann Oncol. 2010 Feb;21(2):428-429. doi: 10.1093/annonc/mdp538. Epub 2009 Nov 17. Ann Oncol. 2010. PMID: 19920059 Review. No abstract available.

Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel.
Sekine I, Ichinose Y, Nishiwaki Y, Yamamoto N, Tsuboi M, Nakagawa K, Shinkai T, Negoro S, Imamura F, Eguchi K, Takeda K, Itoh Y, Tamura T, Saijo N, Fukuoka M. Sekine I, et al. Ann Oncol. 2009 Sep;20(9):1483-1488. doi: 10.1093/annonc/mdp031. Epub 2009 Mar 12. Ann Oncol. 2009. PMID: 19282468 Clinical Trial.